1. Introduction

Non-alcoholic fatty liver disease (NAFLD) is characterized by intra-hepatic fat accumulation and mechanisms involved in its pathogenesis are not fully explained. Lysosomal Acid Lipase (LAL) is a key enzyme in lipid metabolism. We investigated its activity in patients with fatty liver.

LAL activity (nmol/spot/h) was measured in 100 adult healthy subjects (HS) and in 240 NAFLD patients. A sub-analysis on 35 patients with biopsy-proven non-alcoholic steatohepatitis (NASH) was performed. Median LAL activity was 1.15 (0.95–1.72) in HS. It was significantly reduced in NAFLD [0.78 (0.61–1.01), p < 0.001 vs. HS]. A further reduction was observed in the subgroup of NASH [0.67 (0.51–0.77), p < 0.001 vs. HS]. Patients with LAL activity below median had higher values of serum total cholesterol (p < 0.05) and LDL-c (p < 0.05), and increased serum liver enzymes (ALT, p < 0.001; AST, p < 0.01; GGT, p < 0.01). At multivariable logistic regression analysis, factors associated with LAL activity below median were ALT (OR: 1.018, 95% CI 1.004–1.032, p = 0.011) and metabolic syndrome (OR: 0.464, 95% CI 0.248–0.866, p = 0.016). Our findings suggest a strong association between impaired LAL activity and NAFLD. A better knowledge of the role of LAL may provide new insights in NAFLD pathogenesis.

© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
in young adults with CESD was associated with an improvement of liver steatosis (Valayannopoulos et al., 2014).

Our hypothesis was that a reduction of LAL activity may contribute to intracellular fatty acid accumulation in adult NAFLD. Thus, we measured the activity of LAL in a cohort of adult patients affected by NAFLD, and we investigated factors associated with reduced LAL activity.

2. Methods

2.1. Study Design

The study was performed in 240 consecutive patients with ultrasonography (US) evidence of fatty liver, referring to the Day Service of Internal Medicine of the Policlinico Umberto I University Hospital in Rome.

Inclusion criteria were: no history of excessive alcohol consumption defined as a mean daily intake of alcohol > 20 g; no history of Hepatitis C–B viruses infection with negative tests for the presence of hepatitis B surface antigen and antibody to hepatitis C virus; no history for other chronic liver diseases; and no therapy with drugs known to promote liver steatosis (e.g., amiodarone). Subjects underwent routine biochemical evaluation including alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyltransferase (GGT), fasting total and HDL-cholesterol, triglycerides, glucose and insulin. Waist circumference, height and weight were recorded and body mass index (BMI) was calculated.

The homeostasis model of insulin resistance (HOMA-IR) was used as a measure of IR (Matthews et al., 1985). Metabolic syndrome was diagnosed according to the ATP III modified criteria (Anon., 2001). The presence of diabetes and arterial hypertension was defined according to international guidelines (Authors et al., 2013; Mancia et al., 2013).

All patients provided signed informed consent before the study. The study was approved by the local ethical board of Sapienza University of Rome (ref. n° 2277/2011), and conducted according to the ethical principles embodied in the Declaration of Helsinki. Funding source: none.

2.2. Ultrasonography Evaluation of Fatty Liver

Liver US scanning was performed to assess the degree of steatosis. All US were performed by the same operator who was blinded to laboratory values using a GE Vivid S6 apparatus equipped with a convex 3.5 MHz probe. Liver steatosis was defined according to Hamaguchi criteria based on the presence of abnormally intense, high level echoes arising from the hepatic parenchyma, liver–kidney difference in echo amplitude, echo penetration into deep portion of the liver and clarity of liver blood vessel structure (Saverymuttu et al., 1986; Hamaguchi et al., 2007).

2.3. Liver Biopsy

Percutaneous liver biopsy was performed under US guide in 35 of the above fatty liver patients with clinical suspicion of NASH by their treating hepatologists. The decision to perform the biopsy was individualized and based on a persistent elevation of serum alanine aminotransferase levels (>1.5 upper normal values) for more than 6 months and the presence of bright liver at US scan. A single operator performed ultrasound-guided liver biopsies. Pathologist who examined biopsies specimen was blinded to patients’ identity or clinical information. NASH diagnosis was defined using standard criteria (Sanyal et al., 2011). All patients who underwent liver biopsy satisfied histological criteria for NASH.

2.4. Lysosomal Acid Lipase Activity Assay

All blood samples were taken after a 12-hour fast. LAL-activity was dosed with dried blood spot (DBS) technique using the inhibitors Lalistat 2. Ethylene-diamine-tetra acetic acid (EDTA) blood, obtained by venepuncture, was spotted on to filter paper (Whatman grade 903 Schleicher & Schuell) and allowed to dry overnight at room temperature. Samples were stored double-bagged with desiccant at −20 °C and analysed within 2 weeks of storage. Uninhibited and inhibited with Lalistat 2 activities were dosed. LAL activity was determined by subtracting activity in the inhibited reaction from uninhibited reaction (total lipase) and expressed as nmol/spot/h of 4 MU (methylumbelliflorone) (Hamilton et al., 2012). DBS tests were performed in Bambino Gesù Hospital in Rome. Physicians analysing LAL activity were unaware of clinical and biochemical characteristics of any enrolled patient. Inter and intra-assay variations were 2.4% and 2.3%, respectively.

To establish a normal value of LAL activity in adults, we performed DBS tests in 100 normal weight healthy subjects (HS), matched for age and sex with NAFLD patients. HS were not taking any drug or supplement before the blood sample collection, had no ultrasound evidence of fatty liver disease and did not suffer for any acute or chronic disease.

2.5. Statistical Analysis

Distribution of continuous variables was tested using a Kolmogorov–Smirnov test. Data are expressed as the mean ± standard deviation for normally distributed variables and as median followed by the 25th and 75th percentiles in parenthesis for non-normally distributed data. Group comparisons were performed by unpaired Student’s t-test and by Mann–Whitney or Kruskal–Wallis test for non-normally distributed variables.

Proportions and categorical variables were tested by the χ² test or by the two-tailed Fisher’s exact.

For the analyses, we divided the cohort according to the median value of LAL activity. We performed a multivariable logistic regression analysis with LAL activity below median as dependent variable. After testing for collinearity, the following covariates were used for the model: female gender, body mass index, alanine aminotransferase (ALT), statin therapy, anti-hypertensive drug, triglycerides, gamma-glutamyl transpeptidase (γ-GT), and metabolic syndrome. Moreover, a multivariable logistic regression analysis was performed to evaluate the independent predictors of the presence of NASH after controlling for gender, age, platelets, metabolic syndrome, homeostasis model assessment-insulin resistance (HOMA-IR), serum total cholesterol, triglycerides, γ-GT, ALT and LAL activity below median. All tests are two-tailed, and a p < 0.05 was considered as cut-off for statistical significance. Statistical analysis was performed by using the SPSS statistical software version 20.0 for Windows (SPSS Inc., Chicago, Illinois).

3. Results

3.1. LAL Activity in Healthy Subjects

Median blood LAL activity in 100 HS was 1.15 (IQR 0.95–1.72) nmol/spot/h; no difference between males (n = 55) and females (n = 45) [1.08 (0.94–1.70) vs. 1.17 (0.96–1.74) p = 0.486] was found. HS group had mean age of 53.0 ± 11.3 years; LAL activity was not correlated with age (rs = −0.53, p = 0.590).

3.2. Analysis of LAL Activity in NAFLD Patients

Clinical and biochemical characteristics of 240 NAFLD patients are listed in Table 1. Mean age was 55.4 ± 11.0 years; 60.4% were men.

LAL activity was significantly reduced in patients with NAFLD, as compared to those without [1.15 (0.94–1.72) vs. 0.78 (0.61–1.01) nmol/spot/h, p < 0.001]. To investigate factors associated with reduced LAL activity, we divided NAFLD patients in two groups according to the median value of LAL (0.78 nmol/spot/h, Table 2).
We found that NAFLD patients with LAL activity below median had higher values of serum liver enzymes (ALT, \(p < 0.001\); AST, \(p = 0.01\); GGT, \(p = 0.01\)) and LDL-c \(p < 0.05\), and increased serum liver enzymes (ALT, \(p < 0.001\); AST, \(p = 0.01\); GGT, \(p = 0.01\)). Moreover, in the same group of patients a significant lower prevalence of statin therapy (28% vs. 43.3%, \(p < 0.05\)) was present. In addition, values of LAL activity were higher in patients treated with statins compared to those without (Fig. 2).

At multivariable logistic regression analysis (Table 3), factors associated with impaired LAL activity (below median) were ALT (OR: 1.11, 95% CI 1.07–1.16, \(p = 0.01\)) and ALT values (OR: 1.16, \(p = 0.001\)) with the presence of NASH (Fig. 1).

4. Discussion

This is the first study reporting normal values of blood LAL activity in healthy adult subjects; we found a median value of LAL activity of 1.15 nmol/spot/h, with no age and sex differences. We also investigated LAL activity in a cohort of adult patients with NAFLD, and we found a significant reduction of LAL activity in NAFLD patients, compared to healthy subjects. In particular, patients with NAFLD had a 27.0% reduction of LAL activity, which increased to 41.8% in the subgroup of patients with biopsy proven NASH.

Patients with LAL activity below median had a significant elevation of serum liver enzymes and a worse lipid profile (higher total and LDL

### Table 1

| Characteristics of population. |
|--------------------------------|
| **NAFLD patients (N = 240)** |
| Age (years)                  | 55.4 ± 1.0 |
| Male gender (%)              | 60.4 |
| Body mass index (kg/m²)      | 30.5 ± 4.7 |
| Waist circumference (cm)     | 106.0 (101.0–113.8) |
| Diabetes mellitus (%)        | 31.9 |
| Coronary heart disease (%)   | 6.8 |
| Metabolic syndrome (%)       | 70.5 |
| Statin users (%)             | 35.7 |
| Total cholesterol (mg/dl)    | 198.3 ± 38.8 |
| LDL cholesterol (mg/dl)      | 117.5 ± 33.0 |
| HDL cholesterol (mg/dl)      | 48.4 ± 15.6 |
| Triglycerides (mg/dl)        | 146.5 (105.5–187.5) |
| ALT (U/l)                    | 30.0 (21.0–44.0) |
| AST (U/l)                    | 22.0 (18.0–32.0) |
| GGT (U/l)                    | 28.5 (18.0–43.5) |
| Glycaemia (mg/dl)            | 90.0 (100.0–109.0) |
| Insulin (mU/l)               | 14.3 (10.6–20.2) |
| HOMA-IR                      | 3.7 (2.6–5.6) |
| Creatinine (mg/dl)           | 0.9 (0.8–1.0) |

ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transpeptidase; HDL: high-density lipoprotein; HOMA IR: homeostasis model assessment-insulin resistance; LDL: low-density lipoprotein.

* Data expressed as median and interquartile range.

### Table 2

| Clinical and biochemical characteristics of patients with NAFLD above or below the median of Lysosomal Acid Lipase (LAL) activity. |
|--------------------------------------------------------------------------------------------------------------------------|
| LAL activity ≥0.78 nmol/spot/h (N = 120) | LAL activity <0.78 nmol/spot/h (N = 120) | p       |
| Age (years)                  | 55.0 ± 11.0          | 56.0 ± 11.0          | ns      |
| Male gender (%)              | 63.4                 | 59.5                 | ns      |
| Body mass index (kg/m²)      | 30.6 ± 4.7           | 30.4 ± 4.7           | ns      |
| Waist circumference (cm)*    | 106.0 (101.0–114.0)  | 105.0 (100.0–113.0)  | ns      |
| Diabetes mellitus (%)        | 31.5                 | 33.3                 | ns      |
| Coronary heart disease (%)   | 5.9                  | 7.6                  | ns      |
| Metabolic syndrome (%)       | 76.1                 | 65.0                 | 0.07    |
| Statin users (%)             | 28.0                 | 43.3                 | <0.05   |
| Total cholesterol (mg/dl)    | 203.9 ± 40.8         | 192.8 ± 36.1         | <0.05   |
| LDL cholesterol (mg/dl)      | 122.4 ± 32.1         | 112.7 ± 32.2         | <0.05   |
| HDL cholesterol (mg/dl)      | 47.6 ± 17.7          | 49.2 ± 13.2          | ns      |
| Triglycerides (mg/dl)*       | 147.0 (112.0–177.0)  | 146.0 (103.0–195.0)  | ns      |
| ALT (U/l)*                   | 35.0 (24.0–53.0)     | 26.0 (20.0–37.0)     | <0.01   |
| AST (U/l)*                   | 23.0 (19.0–35.0)     | 21.0 (18.0–27.0)     | <0.01   |
| γ-GT (U/l)*                  | 62.0 (21.0–51.0)     | 25.0 (17.0–42.0)     | <0.01   |
| Glycaemia (mg/dl)            | 101.0 (90.0–115.0)   | 97.0 (88.0–122.0)    | ns      |
| Insulin (mU/l)*              | 15.2 (10.5–21.6)     | 13.7 (10.6–19.5)     | ns      |
| HOMA-IR*                     | 3.9 (2.5–5.8)        | 3.3 (2.6–5.6)        | ns      |
| Creatinine (mg/dl)*          | 0.9 (0.8–1.0)        | 0.9 (0.8–1.0)        | ns      |

ALT: alanine aminotransferase; AST: aspartate aminotransferase; γ-GT: gamma-glutamyl transpeptidase; HDL: high-density lipoprotein; HOMA IR: homeostasis model assessment-insulin resistance; LDL: low-density lipoprotein.

* Data expressed as median and interquartile range.
cholesterol). This last finding is in keeping with data by Muntoni S et al. showing a similar lipid profile with a polygenic hypercholesterolemia phenotype in EBOS M LAL mutation carriers (Muntoni et al., 2013).

Of note, there are no data in the literature on the correlation between circulating and hepatic LAL activity, and there is no general histology did not improve with statins (Reiner et al., 2014). Interestingly, dyslipidaemia persisted despite the lipid-lowering treatment, and liver other interesting help to differentiate patients with a major LAL deficiency of metabolic syndrome. Nevertheless, measurement of LAL activity may contribute to the onset of dyslipidaemia typical in hepatocytes.

LAL activity was inversely associated with ALT values and with the presence of metabolic syndrome, whilst statin use was associated to higher LAL values, at multivariable analysis. The inverse association between LAL and ALT values may suggest that impaired LAL activity is associated with liver damage. This finding is partially supported by the further reduction of LAL activity observed in patients with biopsy-proven NASH. However, whether low LAL activity contributes to liver damage progression, or is itself a consequence of liver failure is still unknown.

Of particular interest is the inverse association between metabolic syndrome and LAL activity. This finding may indicate a dual relationship between the activity of LAL and the presence of metabolic risk factors. Thus, we do not know if metabolic factors modulate LAL activity or if, in turn, LAL activity may contribute to the onset of dyslipidaemia typical of metabolic syndrome. Nevertheless, measurement of LAL activity may help to differentiate patients with a major LAL deficiency-related NAFLD, from those with NAFLD due to metabolic syndrome.

The association between statin use and improved LAL function is an another interesting finding of the study. The use of statins is controversial in patients with genetic deficiency of LAL, as in some CESD patients dyslipidaemia persisted despite the lipid-lowering treatment, and liver histology did not improve with statins (Reiner et al., 2014). Interestingly, Fouchier and Defesche (Fouchier and Defesche, 2013) proposed a combined approach with statins and LAL replacement therapy in patients with mutations of Lysosomal Acid Lipase gene.

Our data suggest that in adult non-genetic LAL deficiency, statin could modulate epigenetic expression of this enzyme or potentiate its activity. However, it is unclear whether statins directly influence LAL activity, perhaps as the result of a pleiotropic effect or, alternatively, modulate it through their cholesterol-lowering activity. Nevertheless, the causal relationship cannot be explored in the present study, and an ad hoc interventional study is needed.

Finally, it has been recently reported that LAL released by macrophages in the extracellular space contributes to modification of LDL within the artery wall (Dubland and Francis, 2015). The Authors speculated that early stage atherosclerosis may involve normal or increased LAL activity, whereas later stages of atherosclerosis may have an acquired dysfunction in LAL hydrolytic activity leading to lysosomal cholesterol sequestration. Thus, LAL may represent one possible mechanism contributing to the accelerated atherosclerosis and increased cardiovascular risk reported in patients with NAFLD (Sookoian and Pirola, 2008; Pastori et al., 2015b). However, further research on this issue is needed.

### 4.1. Limitations of the Study

A major limitation of this study is that it is a cross-sectional study, and we therefore cannot establish a cause–effect relationship between the reduction of LAL activity and the presence of NAFLD/NASH. The association between LAL activity and NAFLD/NASH should be confirmed by a prospective study to evaluate the predictive value of LAL on the progression of fatty liver disease. A further limitation is that this is a single centre study performed in consecutive patients with US evidence of fatty liver referred to a metabolic clinic.

### 5. Conclusions

In conclusion, our findings suggest a strong association between impaired LAL activity and fatty liver disease. Our findings need to be confirmed in a larger sample of NASH patients, to establish if LAL measurement may represent a non-invasive marker of NASH. A better knowledge of the role of LAL may provide new insights in the pathogenesis and progression of NAFLD.

### Declaration of Interests

None.

### Research in Context

Lysosomal Acid Lipase (LAL) is a hydrolase with a key role in intracellular cholesterol trafficking. Genetically-determined deficiency of LAL is associated with fatty liver.

We hypothesized whether a reduction of LAL activity may be found with adult NAFLD. We measured the activity of LAL in a cohort of adult NAFLD patients. We found a significant decrease of LAL activity in NAFLD patients compared to healthy subjects, with a further reduction in a subgroup of biopsy-proven NASH. Low LAL activity was directly associated with ALT values and metabolic syndrome, and inversely with statin use.

### Author Contributions

FB and DP equally contributed to the data analysis and interpretation and the paper writing; MDB, LP and SDS contributed to patient recruitment, data collection and interpretation; GL performed liver biopsies; FP and GT performed laboratory determinations; FV and FA did the study design and wrote the manuscript.

### Table 3

Multivariate logistic regression analysis of factors associated with reduced Lysosomal Acid Lipase activity (below median).

| Factor                    | B    | SE   | Beta | p value | 95.0% C.I. for B |
|---------------------------|------|------|------|---------|-----------------|
| Age                       | 0.005| 0.014| 1.005| 0.744   | 0.977–1.034     |
| Female gender             | -0.023| 0.298| 0.977| 0.938   | 0.545–1.752     |
| Body mass index           | -0.020| 0.033| 0.980| 0.539   | 0.919–1.045     |
| ALT                       | 0.018| 0.007| 1.018| 0.011   | 1.004–1.032     |
| Statin therapy            | -0.768| 0.318| 0.464| 0.016   | 0.248–0.866     |
| Anti-hypertensive drugs   | -0.160| 0.330| 0.852| 0.628   | 0.447–1.626     |
| Triglycerides             | 0.000| 0.001| 1.000| 0.630   | 0.998–1.001     |
| γ-GT                      | 0.003| 0.003| 1.003| 0.293   | 0.998–1.008     |
| Metabolic syndrome        | 0.537| 0.368| 2.531| 0.011   | 1.241–5.245     |

ALT: alanine aminotransferase; γ-GT: gamma-glutamyl transpeptidase.
Acknowledgements

We thank Nurse Daniela Salzano for the skilful collaboration.

References

Angelico, F., Del Ben, M., Conti, R., et al., 2005. Insulin resistance, the metabolic syndrome, and non-alcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 90 (3), 1578–1582.

Angelico, F., Burattini, M., Alessandri, C., Del Ben, M., Lirussi, F., 2007. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst. Rev. 1 (CD005166).

Anon., 2001. Expert panel on detection E, treatment of high blood cholesterol in A.

Authors, Task Force, M., Ryden, L., Grant, P.J., et al., 2013. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur. Heart J. 34 (39), 3035–3087.

Bellentani, S., Saccoccio, G., Masotti, F., et al., 2000. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 132 (2), 112–117.

Bernstein, D.L., Hulkova, H., Bialer, M.G., Desnick, R.J., 2013. Cholesteryl ester storage disease: review of the findings in 135 reported patients with an undiagnosed disease. J. Hepatol. 58 (6), 1230–1243.

Chalasani, N., Younossi, Z., Lavine, J.E., et al., 2012. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55 (6), 2005–2023.

Compare, D., Cocoli, P., Rocco, A., et al., 2012. Gut–liver axis: the impact of gut microbiota on non-alcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis. NMCDD 22 (6), 471–476.

Corey, K.E., Vuppalanchi, R., Vos, M., et al., 2015. Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J. Pediatr. Gastroenterol. Nutr. 60 (3), 360–367.

Del Ben, M., Polimeni, L., Carnevale, R., et al., 2014a. NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 14 (1), 81.

Del Ben, M., Polimeni, L., Branconi, M., et al., 2014b. Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants. Eur. J. Intern. Med. 25 (6), 566–570.

Del Ben, M., Polimeni, L., Baratta, F., Pastori, D., Loffredo, L., Angelico, F., 2014c. Modern approach to the clinical management of non-alcoholic fatty liver disease. World J. Gastroenterol. WJG 20 (26), 8341–8350.

Dubland, J.A., Francis, G.A., 2015. Lysosomal acid lipase: at the crossroads of normal and atherogenic cholesterol metabolism. Front. Cell Dev. Biol. 3, 3.

Farrell, C.C., Larson, C.Z., 2006. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 (2 Suppl 1), S99–S112.

Fasano, T., Pisciotta, L., Bocchi, L., et al., 2012. Lysosomal lipase deficiency: molecular characterization of eleven patients with Wolman or cholesteryl ester storage disease. Mol. Genet. Metab. 105 (3), 450–456.

Foucher, S.W., Defesche, J.C., 2013. Lysosomal acid lipase A and the hypercholesterolaemic phenotype. Curr. Opin. Lipidol. 24 (4), 332–338.

Hamaguchi, M., Kojima, T., Itoh, Y., et al., 2007. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am. J. Gastroenterol. 102 (12), 2708–2715.

Hamilton, J., Jones, I., Srivastava, R., Galloway, P., 2012. A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalizact 2. Clin. Chim. Acta Intl. J. Clin. Chem. 413 (15–16), 1207–1210.

Kemmer, N., Neff, G.W., Franco, E., et al., 2013. Nonalcoholic fatty liver disease epidemic and its implications for liver transplantation. Transplantation 96 (10), 860–862.

Mancia, G., Fagard, R., Narkiewicz, K., et al., 2013. 2013 practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). ESH/ESC task force for the management of arterial hypertension. J. Hypertens. 31 (10), 1925–1938.

Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (7), 412–419.

Muntoni, S., Wiebusch, H., Jansen-Rust, M., et al., 2013. Heterozygosity for lysosomal acid lipase ESBM mutation and serum lipid concentrations. Nutr. Metab. Cardiovasc. Dis. NMCDD 23 (8), 732–736.

Pastori, D., Polimeni, L., Baratta, F., Pani, A., Del Ben, M., Angelico, F., 2015a. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig. liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Stud. Liver 47 (1), 4–11.

Pastori, D., Loffredo, L., Perri, L., et al., 2015b. Relation of nonalcoholic fatty liver disease and Framingham risk score to flow-mediated dilation in patients with cardiometabolic risk factors. Am. J. Cardiol. 115 (10), 1402–1406.

Pisciotta, L., Fresa, R., Belloccchio, A., et al., 2009. Cholesteryl ester storage disease (CESD) due to novel mutations in the LIPA gene. Mol. Genet. Metab. 97 (2), 143–148.

Puri, P., Baille, R.A., Wiest, M.M., et al., 2007. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46 (4), 1081–1090.

Reiner, Z., Guardamagna, O., Nair, D., et al., 2014. Lysosomal acid lipase deficiency—an under-recognized cause of dyslipidaemia and liver dysfunction. Atherosclerosis 235 (1), 21–30.

Reynolds, T., 2013. Cholesteryl ester storage disease: a rare and possibly treatable cause of premature vascular disease and cirrhosis. J. Clin. Pathol. 66 (11), 918–923.

Sanjay, A.J., Brunt, E.M., Klein, D.E., et al., 2011. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 54 (1), 344–353.

Sanjay, A.J., Friedman, S.L., McCullough, A.J., Dimick, L., Apr 2015. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an american association for the study of liver diseases (asld)–food and drug administration (fda) joint workshop. Hepatology 61 (4), 1392–1405. http://dx.doi.org/10.1002/hep.27678.

Savemyrutm, S.H., Joseph, A.E., Maxwell, J.D., 1986. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br. Med. J. 292 (6512), 13–15.

Singh, R., Kaushik, S., Wang, Y., et al., 2009. Autophagy regulates lipid metabolism. Nature 458 (7242), 1131–1135.

Sooki, A.A., Gorlov, C.J., 2008. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J. Hepatol. 49 (4), 600–607.

Thelwall, P.E., Smith, F.E., Leavitt, M.C., et al., 2013. Hepatic cholesteryl ester accumulation in lysosomal acid lipase deficiency: non-invasive identification and treatment monitoring by magnetic resonance. J. Hepatol. 59 (3), 543–549.

Valanymopoulos, V., Malinova, V., Housz, T., et al., 2014. Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency. J. Hepatol. 61 (5), 1135–1142.

Vernon, G., Baranov, A., Younossi, Z.M., 2011. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34 (3), 274–285.